
Sign up to save your podcasts
Or


Welcome to Chasing Compliance, the GLOBAL regulatory podcast, where we discuss all aspects of medical device and pharmaceutical regulatory and clinical strategy – from bench to bedside.
Today we are chatting with Emily Stephens, the founder and CEO of GLOBAL. Emily worked in the medical device and biologics industries for thirteen years before launching GLOBAL in early 2014. After years of 60-hour work weeks for CROs that were notorious for burning out workers, she developed an autoimmune disease that would forever change her vision of the medical writing industry. Life was too short for burnout. She wondered: What would happen if there was a company that treated workers with respect, loyalty, and deeply advocated for their work/life balance? Out of this question GLOBAL was born and the outcome has been spectacular: We attract the best, who then perform at their best, because this is a place where we fiercely take care of each other.
Thank you for being here, Em! On this episode, we are exploring 2026 – what are we looking forward to, what are we looking out for, and what opportunities exist. Let’s dive in!
Welcome to Chasing Compliance, the GLOBAL regulatory podcast, where we discuss all aspects of medical device and pharmaceutical regulatory and clinical strategy – from bench to bedside.
Today we are chatting with Violet Chazovachii. Violet has spent almost a decade in the biomedical technology field. As a graduate researcher at the University of Michigan Ann Arbor, she focused on developing surface coatings to optimize microparticles for vascular targeted drug delivery. After earning her master’s degree, she joined Global’s CER internship program in 2021 and has advanced to the role of Lead Medical Writer, where she continues to contribute to high-impact regulatory submissions. Violet recently earned her RAC (Regulatory Affairs Certification) in Medical Devices
Thank you for being here Violet! On this episode, we are discussing RAPS convergence 2025. We sent a team to this conference and had a wonderful experience connecting with regulatory affairs peers and learning the latest developments and trends in US and global healthcare regulations. Violet was one of our teammates on the ground and has some great insights from the week. Let’s dive in!
Welcome to Chasing Compliance, the GLOBAL regulatory podcast, where we discuss all aspects of medical device and pharmaceutical regulatory and clinical strategy – from bench to bedside.
Today we are chatting with Julie Matison and Scott Michaels.
Julie Matison holds a Bachelor’s degree in Chemical Engineering and a Master’s degree in Mechanical Engineering, and recently earned the RAC-Drugs certification through RAPS. She has over 21 years of experience in the pharmaceutical industry, with a strong background in manufacturing, validation and quality.
Scott Michaels earned his Master’s in Pharmaceutical Chemistry from the University of Kansas and his Bachelor’s in Chemistry from McGill University. He has held a variety of regulatory and CMC product development roles over the past 20 years, working with both small molecules and biologics.
Thank you both for being here! On this episode, we are discussing CMC strategy around biologics IND submissions. I am sure our audience is looking forward to your insights, so let’s dive in.
Welcome to Chasing Compliance, the Global Regulatory Writing and Consulting podcast where we discuss all aspects of medical device and pharmaceutical regulatory and clinical strategy from bench to bedside. Today we are chatting with Eimile Oakes and Andrew Stephens, discussing Clinical Study Reports, also known as CSRs. CSRs must tell a clear, compliant, and credible story of a clinical trial. With so many moving parts and often tight timelines, getting it right requires expertise. Tune in to hear their advice on how to deliver these documents with accuracy and efficiency!
Welcome to Chasing Compliance, the Global Regulatory Writing and Consulting podcast where we discuss all aspects of medical device and pharmaceutical regulatory and clinical strategy from bench to bedside. Today we are chatting with Beth Meier and Luke Baker about how to prepare airtight CERs.
This episode of Chasing Compliance is for those working on regulatory submissions for in-vitro diagnostic (IVD) medial devices. Today we talk to our resident Performance Evaluation Report (PER) expert, Bethany Hosford provides suggestions on how to improve your EU IVD regulatory submissions including PERs and their associated documents.
2:15 – Brief background of the In vitro Diagnostic Regulation (IVDR) and the Performance Evaluation Report (PER)
3:15 – Items to tackle prior to beginning to write PER
4:15 – Bethany’s recommendation for starting the PER process
6:30 – Tips for finding clinical data or addressing gaps for challenging IVDs. Bethany answers the question, what do you do if you device is mentioned in several articles, but it isn’t a focus?
9:15 – Do you need to consider your audience when preparing a PER? If yes, how should you do that?
10:30 – What is the best approach for reviewing and summarizing data? Should it be done piecemeal or holistically.
12:00 – Tips for writing associated documents such as the Analytical Performance Report (APR), Scientific Validity Report (SVR), and Clinical Performance Report (CPR).
14:10 – What is required to determine scientific and clinical validity in the case of a companion diagnostic (CDx) or other IVD? Where is this information found? BRCA – Gene which is highly associated with the development of breast cancer
18:00 – When is enough data enough? How do you know you have enough clinical data? What if you don’t have clinical data, what should you do?
20:45 – Bethany’s tips for preparing to write a PER. Key takeaways:
24:45 – What to do if you find you are missing data or have data gaps during the writing process.
28:45 – What should you do if you don’t fully understand the device you are working on or how to best summarize clinical or analytical data?
30:15 – Summary of topics discussed up to this point and Bethany’s tips for staying organized throughout the PER writing process.
33:45 – Generally, how long does it take to write a PER? What are your tips for pacing?
35:15 – Bethany’s tips for finalizing a PER.
40:00 – What is the value of templates in the PER writing process?
Ready to take your technical writing to the next level, but not sure where to start? Would you like to learn some tips to freshen up your writing approach? In this episode and the next we share more of our favorite tips and tricks for technical writing. Our guide, Jennifer Petrie Signore, PhD has spent years working to become the best and most versatile technical writer possible, and she shares her tips with you. In this episode, we cover a wide range of topics, such as:
1:30 – Recap of last episode.
2:30 – What is Jenn’s process for finishing a document.
5:15 – How to make Microsoft Word work for you and speed up your writing process. Jenn discusses tools within word which help improve the writing process, such as:
9:45 – Other types of software which may help your writing process, such as:
17:30 – Jenn provides her tips for finalizing documents including how to conduct final editing and revision activities. In summary:
22:00 – Review as a team effort: tips for leveraging teammates and colleagues. When is it time to hand a document over? When is it appropriate to reach out for feedback?
31:45 – Final thoughts, summary, and wrap-up
Ready to take your technical writing to the next level, but not sure where to start? Would you like to learn some tips to freshen up your writing approach? In this episode and the next we dive into some of our favorite tips and tricks for technical writing. Our guide through the next two episodes is Jennifer Petrie Signore, PhD. From the start of her graduate training, Jenn was focused on becoming the best and most versatile technical writer she possibly could be. In this short series, Jenn shares what she has learned throughout her 15+ years of technical writing experience. In this episode, we cover a wide range of topics, such as:
We cover a lot of information in this episode. If you miss something, we’ve summarized the key points below.
2:00 – Jennifer’s provides some background on her technical and scientific writing training and experience. Jamie and Jenn briefly discuss the importance of writing quality and skill in the technical disciplines and options for training.
10:00 – Are there any general misconceptions or mistakes you would like to address right out of the gate?
13:25 – Starting the process: how to use templates and instructions to create a strong foundation. Use the template to guide your writing. Make sure you follow the instructions and providing the information the reader is looking for.
19:25 – How to know how much detail to include? When is it time to “go down the rabbit hole?” When is it appropriate to provide a high-level summary? Look for rubrics and previous work. Don’t hesitate to reach out to the client or the audience.
29:10 – The importance of clarity in technical writing. Tips and tricks for improving clarity.
37:40 – Jennifer’s tips for getting unstuck or moving through challenging sections. Leave yourself landmarks.
41:00 – Overall episode summary.
44:00 – What are we going to cover in part 2?
This episode is Part 2 of a two-part episode on Abbreviated New Drug Applications (ANDAs). We continue our conversation with our ANDA expert Sandra Kircus. In this part, Sandra provides advice on how to manage ANDA projects, the importance of strong project management, and provides suggestions for project management tools. She also shares her thoughts on how to regulatory leaders can optimize the ANDA writing process and how to optimize the ANDA process fro companies outside of the United States referred to as xUS companies. Sandra and Jamie discuss why having strong US agent for xUS companies is important. While this advice is focused on xUS companies, it also rings true for US companies as well.
2:30 – Tips for general approach to writing ANDAs
5:40 – Tips for the ANDA writing process
8:00 – Software for Program Management
10:30 – Proportion of applications from US companies and outside or xUS companies. Implications for xUS companies and role of US agents.
From the publisher's feed

13,934 Listeners

16 Listeners